Takeda walks away from Omontys
Takeda and Affymax are parting ways. PMLive reports that Takeda is withdrawing its US marketing application for the anemia drug Omontys and that Affymax is not looking to pick the marketing rights up.
The companies had to recall the drug last year after several patient deaths and allergic reactions. Takeda told PMLive that it looked into the reactions and found they could not be attributed to quality or manufacturing issues.
PMLive says Affymax had three employees as of March, and was running a deficit of around $560 million.